The O’Neill extended campus at Northeast Community College is offering two courses that begin in late February designed to meet regional workforce and professional development needs.

–Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept (“POC”) Study in Treatment Resistant Depression (“TRD”) in the Second Half of 2026– ...

Explore the impact of AI in drug discovery as 2026 promises critical clinical results and industry transformations.

In the pursuit of solutions to complex global challenges including disease, energy demands, and climate change, scientific ...

Jan 14 (Reuters) - The U.S. Food and Drug Administration and the European Medicines Agency jointly issued principles for safe and responsible use of artificial intelligence in developing medicines, ...

An experimental drug called NU-9 has shown promise as an early intervention for Alzheimer’s disease. The corresponding study was published in Alzheimer’s & Dementia. "Alzheimer's disease begins ...

Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...

IQVIA Holdings is positioned as the indispensable data and technology backbone of the life sciences industry, far beyond a traditional CRO. Long-term revenue visibility is underpinned by a record ...

In the final part of his Pharma Commerce video interview, Ed Schoonveld, value and access advisor for Schoonveld Advisory and author of The Price of Global Health, previews his December column, ...

Dec 3 (Reuters) - Excelsior Sciences said on Wednesday it has raised $95 million to develop technology that uses machines and artificial intelligence to accelerate the development and testing of small ...

The FDA has proposed new policies to speed up the development and lower the cost of biosimilar agents for cancer and other serious illnesses. These policies include “major updates to simplify ...